We examined the role of spinal tumor necrosis factor-alpha (TNFa) in neuropathic pain of peripheral nerve origin. Two weeks after selective L5 spinal nerve ligation (SNL), rats exhibiting mechanical allodynia and thermal hyperalgesia showed a marked increase in full-length membrane-associated TNFa (mTNFa) in the dorsal horn of spinal cord, in the absence of detectable soluble TNFa peptide. Local release of the soluble p55 TNF receptor, achieved by herpes simplex virus vector-based gene transfer to dorsal root ganglion, resulted in a reduction of mTNFa and concomitant reductions in interleukin-1b and phosphorylated p38 MAP kinase. Subcutaneous inoculation of soluble p55 TNF receptor expressing HSV vector into the plantar surface of the hind foot ipsilateral to the ligation 1 week before SNL delayed the development of both mechanical allodynia and thermal hyperalgesia; subcutaneous inoculation into the hind foot ipsilateral to the ligation 1 week after SNL resulted in a statistically significant reduction in mechanical allodynia and thermal hyperalgesia that was apparent 1 week after inoculation. These results suggest a novel 'reverse signaling' through glial mTNFa, which may be exploited to downregulate the neuroimmune reaction in spinal cord to reduce chronic neuropathic pain.
Introduction
Chronic neuropathic pain resulting from injury or damage to structures in the peripheral nervous system is a significant clinical problem that is difficult to treat effectively using currently available therapies.
1,2 An emerging body of work indicates that the transition to the chronic neuropathic pain state involves activation of glia in the dorsal horn of spinal cord with the consequent release of proinflammatory cytokines [3] [4] [5] [6] In that process, tumor necrosis factor-alpha (TNFa) plays an important role. In response to peripheral nerve crush, the amount of TNFa in spinal astrocytes and microglia is increased. 7 In the chronic constriction injury model of peripheral neuropathic pain, neutralizing antibodies directed against TNFa or the p55 TNF receptor (TNFR) reduce thermal hyperalgesia and mechanical allodynia, 8 and intrathecal administration of the recombinant p75 soluble TNFR (sTNFR) peptide (etanercept) before selective spinal nerve ligation (SNL) reduces mechanical allodynia 9, 10 in that model. TNFa is a member of the superfamily of type II transmembrane proteins containing an intracellular Nterminus that are biologically active as self-assembling non-covalent bound trimers. 11 The full-length membrane-spanning TNFa (mTNFa) is cleaved by the inducible TNF converting enzyme (TACE) 12 to release a diffusible peptide (soluble TNFa (sTNFa)). 13 sTNFa is a short-lived inflammatory mediator that plays a central role in initiating inflammatory reactions of the innate immune system, including induction of cytokine production, activation and expression of adhesion molecules, and stimulation of inflammatory cells. Through binding to the p55 TNFR, sTNFa activates the transcription factors AP-1 and nuclear factor-kB (NF-kB) to promote the production of proinflammatory cytokines including interleukin-1b (IL-1b) and TNFa. Both IL-1b and TNFa activate and are activated by NF-kB, creating a positive regulatory loop that may amplify and perpetuate local inflammatory responses. 14, 15 The activity of sTNFa is terminated in part by binding to cleaved soluble forms of the TNFR (p55 or p75 sTNFR). Recombinant p75 sTNFR has substantial anti-inflammatory properties and is used in the treatment of several inflammatory conditions.
In the immune system, the full-length transmembrane mTNFa serves to mediate bidirectional cell-to-cell interactions through binding to the membrane receptor complex (p55 or p75 TNFR) on neighboring cells. Similar to other members of the TNF superfamily, in immune cells the membrane-anchored ligand has been demonstrated to transduce 'reverse' signals into the ligandexpressing cell when activated by the cognate receptor(s). 16, 17 To elucidate the role of spinal TNF in the pathogenesis of neuropathic pain, we used viral vector-mediated transfer of the gene coding for the p55 sTNFR antagonist of TNFa to the dorsal root ganglion (DRG) to release p55 sTNFR into the dorsal horn of spinal cord in rats with neuropathic pain created by selective SNL. These studies implicate spinal mTNFa in the regulation of central neuroimmune activation in neuropathic pain.
Results
We have demonstrated previously that the non-replicating herpes simplex virus (HSV) vector T0TNFsR ( Figure  1 ) produces p55 sTNFR in primary DRG neurons in culture in vitro, 18 and in lumbar DRG in vivo following subcutaneous inoculation with the vector in the hind foot of rats, 18 and that transgene-mediated sTNFR is transported to the terminals of primary afferents in the spinal cord. 18 Control vector T0Z.1 was identical to T0TNFsR except that it contained the Escherichia coli lacZ gene in place of p55 sTNFR.
Inoculation with either T0TNFsR or T0Z.1 subcutaneously in the hind feet of uninjured rats resulted in no change in either the mechanical or thermal threshold over the course of 3 weeks (Figure 2 ), indicating that expression of p55 sTNFR does not alter sensory function in normal rats. Selective ligation of the L5 spinal nerve 19, 20 resulted in neuropathic pain characterized by mechanical allodynia and thermal hyperalgesia. Subcutaneous inoculation with T0TNFsR (30 ml containing 2 Â 10 8 plaque-forming units/ml) in the plantar surface of the hind foot ipsilateral to the SNL 1 week before SNL delayed the development of both mechanical allodynia and thermal hyperalgesia (Figure 3a and b) for a period of 4 weeks. By 5 weeks after inoculation, the mechanical threshold of T0TNFsR-inoculated rats was indistinguishable from that of the T0Z.1-inoculated controls; this time course of the transgene-mediated effect is consistent with the time course we have observed for transgene expression driven by other immediate early promoters from latent HSV vectors. 20, 21 Although the thermal threshold remained essentially unchanged in T0TNFsR-inoculated rats, in this model thermal hyperalgesia resolves spontaneously over the course of 5-6 weeks so that the full duration of the vector-mediated effect cannot be established.
Subcutaneous inoculation of T0TNFsR into the plantar surface of the hind foot ipsilateral to the ligation 1 week after SNL resulted in a statistically significant reduction in mechanical allodynia and thermal hyperalgesia that was apparent 1 week after inoculation. The vectormediated effect on mechanical allodynia peaked 2 weeks after inoculation before waning; the reduction in thermal hyperalgesia persisted through the course of observation, as control vector-inoculated animals showed spontaneous resolution of this phenomenon (Figure 3c and d) .
SNL resulted in an approximate eightfold increase in mTNFa in dorsal horn measured by Western blot performed 2 weeks after SNL ( Figure 4 ). We were unable to detect sTNFa in the soluble fraction of a dorsal horn homogenate by enzyme-linked immunosorbent assay (ELISA) (data not shown) at the same time point. Animals inoculated with the p55 sTNFR-expressing vector 1 week after SNL showed no increase in mTNFa compared with sham-operated animals ( Figure 4 ). The cellular localization of mTNFa in the spinal cord was determined by confocal microscopy of immunocytochemical sections co-labeled with the microglial marker OX-42 or the astrocytic marker glial fibrillary acidic protein (GFAP). TNFa was found diffusely along GFAPlabeled astrocytic processes ( Figure 5a ) and in a restricted focal distribution in OX-42-labeled microglia ( Figure 5b) .
It has been shown that non-noxious touch induces expression of the immediate early gene c-Fos in secondorder nociceptive neurons in the dorsal horn of rats with neuropathic pain from SNL. 22 We compared this parameter in animals inoculated with either T0TNFsR or T0Z.1 1 week after SNL and sacrificed 2 h after 10 min of gentle touch applied to the plantar surface of the foot, 2 weeks after SNL. Animals with SNL inoculated with T0Z.1 showed a statistically significant increase in the Previous studies have demonstrated an important role for activation by phosphorylation of p38 in microglia of the spinal cord, 23, 24 release of IL-1b, 25, 26 and TNFa 8, 9 in the development of neuropathic pain. p-p38 immunoreactivity is localized to OX-42-positive microglial cells in the dorsal horn. 27 Animals with SNL inoculated with control vector T0Z.1 showed a statistically significant increase in IL-1b and p-p38a in the dorsal horn of spinal cord, measured by ELISA. These increases were 
Discussion
Central immune activation plays an important role in the development of chronic pathological pain after damage to the nervous system. 5, 6 The evidence includes observations that (1) in rodent models of peripheral neuropathic pain, partial peripheral nerve damage results in activation of glia in the spinal cord;
28 (2) treatments that reduce pain also block glial activation; and (3) disruption of spinal glial activation reduces nocisponsive behaviors. 29, 30 Specific evidence that TNFa plays an important role in this process is provided by studies which have demonstrated that (1) spinal TNFa is increased after nerve injury; 7 (2) application of TNFa sensitizes DRG neurons to painful stimuli; 31, 32 and (3) damaged nerves are hypersensitive to the proalgesic effects of TNFa. 33, 34 Intrathecal administration of the soluble form of p75 TNFR (etanercept) reduces pain-related behaviors and blocks the increase in phosphorylation of MAP kinase p38 in the spinal cord in the SNL model of neuropathic pain. 9 The antinociceptive effect of p75 TNFR in this model was observed only when the peptide was administered before injury. In other studies, intrathecal administration of neutralizing antibodies against the p55 TNFR (but not antibodies against the p75 TNFR) reduce pain in the chronic constriction injury model of peripheral neuropathic pain. 35 In this study, we found that release of p55 TNFR in spinal cord, achieved by transducing DRG neurons with an HSV vector expressing p55 TNFR 2 weeks after SNL, reduced the behavioral manifestations of neuropathic pain while simultaneously reducing the phosphorylation of p38a and the expression of IL-1b and mTNFa in the spinal cord. It is unlikely that this effect occurred as the result of blocking or terminating effects of sTNFa for two reasons. There is no evidence to suggest that sTNFa was present in significant amounts in the spinal cord at this time point, as we were unable to detect sTNFa either by ELISA or Western blot of a soluble extract of spinal cord at 2 weeks after SNL. In contrast, substantial amounts of full-length (26 kDa) mTNFa were detectable by Western blot. Although we cannot exclude the possibility that biologically relevant but undetectable amounts of sTNFa were present, this would be a less likely mechanism to account for the observed effects of sTNFR.
In the immune system, an emerging body of literature suggests that 'reverse' signaling through mTNFa may serve to regulate the immune response. 16, 17, 36, 37 In our studies, it would appear that release of sTNFR from the terminals of transduced DRG neurons binds to mTNFa to activate a reverse signaling mechanism that inhibits the phosphorylation of p38a and reduces expression of TNFa and IL-1b. TACE is responsible for both cleavage and release of sTNFa from mTNFa as well as for the release of p75 sTNFR from p75 TNFR. 38 Release of and TNFa in neuropathic pain S Hao et al binding of the soluble cleaved receptor to sTNFa provides one mechanism that can result in termination of the action of sTNFa. The demonstration in this study that p55 sTNFR can downregulate TNF (and IL-1b) expression by reverse signaling through mTNFa provides a second mechanism. Whether this process occurs directly in microglia, or through cell-cell signaling mediated by astrocyte-expressed TNFa has not been established. We observed recently a similar phenomenon in a model of below-level central neuropathic pain following thoracic spinal cord hemisection, 18 but the possible role of mTNFa in mediating reverse signaling in the nervous system has not previously been characterized.
These results provide a unique model for the function of TNF in the pathogenesis of neuropathic pain. In addition, modulation of mTNFa by vector-mediated gene transfer or other agents may provide a novel therapeutic alternative for the treatment of neuropathic pain.
Materials and methods

Construction of the p55 sTNFR-expressing herpes simplex virus vector
Vector T0TNFsR (Figure 1 ) was generated as described previously. 18, 39 Control vector T0Z.1 is identical to T0TNFsR except that it contains the E. coli lacZ gene in place of p55 sTNFR.
Experimental animals and surgical procedures
Sprague-Dawley rats weighing 225-250 g were housed 1-4 per cage approximately 7 days before the beginning of the study. Animals were given free access to food and water and maintained on a 12:12 light:dark schedule at 211C and 60% humidity. All housing conditions and experimental procedures were approved by the University of Michigan Animal Care and Use Committee. Neuropathic pain was induced by selective ligation of the left L5 spinal nerve. 21, 40 Under chloral hydrate anesthesia (0.3 g/kg), the left L5 spinal nerve was identified, carefully dissected free from the adjacent L4 spinal nerve, and tightly ligated with 6-0 suture. Shamoperated control animals were dissected in an identical manner, but the spinal nerve was not ligated. Animals that showed motor dysfunction of the hind limb after operation were excluded from further analysis. Rats with SNL exhibited a change in ipsilateral foot position and displayed a 'guarding behavior' of ipsilateral hind limb. All the animals exhibited normal weight gain, toenail growth and level of activity. Animals were inoculated subcutaneously into the plantar surface of the left hind paw with 30 ml of vectors T0TNFsR or T0Z.1 (each at a concentration of 2 Â 10 8 plaque-forming units/ml). There was no evidence of distress or abnormally aggressive behavior in any of the animals after inoculation with HSV vector.
Behavioral testing Mechanical allodynia. Rats were placed in transparent plastic cubicles on a mesh floor for an acclimatization period of at least 30 min. Mechanical allodynia was determined by assessing paw withdrawal to von Frey hairs of graded tensile strength. A series of calibrated von Frey filaments (0.4, 0.7, 1.2, 1.5, 2.0, 3.6, 5.5, 8.5, 11.8 and 15.1 g) were presented serially to the hind paw in ascending order of strength, with each filament applied for 6 s with sufficient force to cause slight bending against the paw. A positive response was defined as rapid withdrawal and/or licking of the paw immediately upon application of the stimulus, which was then followed by application of the next finer von Frey filament. After a negative response, the next higher von Frey filament was applied. Animals that did not respond to a pressure of 15.1 g were assigned to this cutoff value. The tactile stimulus producing a 50% likelihood of withdrawal was determined using the updown method. 41, 42 Thermal hyperalgesia. The latency to hind paw withdrawal from a thermal stimulus was determined by exposing the plantar surface of the hind paw to radiant heat using a modified Hargreaves thermal testing device. 43 Briefly, rats were placed in individual enclosures on a glass plate maintained at 301C and a radiant thermal stimulus was positioned underneath the glass plate directly under the hind paw. Activation of the bulb simultaneously activated a timer, and both were immediately turned off by paw withdrawal or at the 20 s cut-off time.
Immunohistochemistry
Immunohistochemical expression of spinal c-Fos was investigated as described previously. 44 A gentle touch was applied once every 4 s for 10 min with the flat surface of the experimenter's thumb to the rat paw. 22 Each stimulus was moved from the middle of the foot to the distal footpad over the course of 2 s in a manner that would not elicit a flexion reflex in normal rats. Two hours after completion of stimulation, the animals were perfused with 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS). The spinal cord was postfixed, cryoprotected and 35 mm transverse cryosections of L4-5 segments incubated overnight at 41C with anti-cFos (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA) followed by biotinylated goat anti-rabbit immunoglobulin G, (1:100; Vector Laboratories, Burlingame, CA, USA) and detected with diaminobenzidine (Vectastain Elite ABC Kit, Vector Laboratories) as described previously. 45, 46 Seven to 10 sections from each animal were randomly selected and the expression of Fos-LI was evaluated by a blinded observer counting the number of immunopositive cells in the gray matter of ipsilateral spinal cord. For purposes of laminar distribution, regions were defined as superficial dorsal horn (laminae I-II, superficial), nucleus proprius (laminae III-IV), neck of the dorsal horn (laminae V-VI) and total laminae (laminae I-X).
For fluorescence detection, cryosections were probed with anti-TNFa (1:100; Santa Cruz Biotechnology, or Abacam, Cambridge, MA, USA) together with either anti-GFAP (1:1000; Sigma-Aldrich, St Louis, MO, USA) or anti-OX-42 (1:500; BD Pharmigen, San Jose, CA, USA), complementary secondary antibodies labeled with Alexa 488 or Alexa 594 (Molecular Probes, Eugene, OR, USA) and photographed using a Zeiss LSM 510 confocal microscope.
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ELISA
Two weeks after inoculation with vectors, the L4-5 spinal dorsal horn ipsilateral to the SNL was removed, frozen on dry ice and stored at À801C. The tissue was minced and placed in 0.3 ml of ice-cold homogenization buffer containing 1 protease inhibitor cocktail tablet (Roche, Mannheim, Germany) per 50 ml, as described previously. 45 To determine the relative amounts of IL-1b and p-p38a, the L4-5 ipsilateral dorsal quadrant of lumbar spinal cord was processed in an identical fashion and peptide levels determined using specific ELISA kits (R&D Systems, Minneapolis, MN, USA).
Western blotting
Under deep anesthesia with chloral hydrate, the L4-5 dorsal horn ipsilateral to SNL was removed rapidly, frozen on dry ice, and stored at À801C. Tissue was homogenized in 1% NP-40 lyses buffer that contained a mixture of proteinase and phosphatase inhibitors. The protein concentration of tissue lysates was determined with a BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL, USA), and 30 mg of protein was loaded in each lane. Protein samples were separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel (12% gradient gel; Bio-Rad, Hercules, CA, USA) and transferred to polyvinylidene difluoride membranes (Millipore Corp., Bedford, MA, USA). The filters were blocked with 5% milk in PBS with 0.1% Tween 20 for 1 h at room temperature, and incubated overnight at 41C with anti-TNFa antibody (anti-rabbit, 1:1000; Santa Cruz Biotechnology). The blots were incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary antibody (1:2000; Santa Cruz Biotechnology), developed in chemiluminescence solution (Pierce Biotechnology) for 1 min, and exposed onto films for 3-30 min. mTNFa levels were normalized using the amount of b-actin as a standard.
Data analysis
The statistical significance of differences between groups was evaluated by analysis of variance (ANOVA) followed by Fisher's PLSD post hoc test (StatView 5.0, SAS Institute, Cary, NC, USA). For repeated measures of behavioral function, the general linear model for repeated measures was used to identify significant effects of treatment condition on the behavioral measure of neuropathic pain (SPSS Inc., Chicago, IL, USA). All data are presented as mean7s.e.m.
